Treatment Response and Long Term Follow-up Results of Nonspecific Interstitial Pneumonia.
10.3346/jkms.2012.27.6.661
- Author:
Ji Yeon LEE
1
;
Sang Man JIN
;
Byoung Jun LEE
;
Doo Hyun CHUNG
;
Bo Gun JANG
;
Heae Surng PARK
;
Sang Min LEE
;
Jae Joon YIM
;
Seok Chul YANG
;
Chul Gyu YOO
;
Sung Koo HAN
;
Young Soo SHIM
;
Young Whan KIM
Author Information
1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine, Seoul, Korea. ywkim@snu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Idiopathic Interstitial Pneumonias;
Lung Diseases, Interstitial;
Pulmonary Fibrosis;
Disease Progression;
Mortality;
Prednisolone;
Prognosis;
Recurrence;
Steroids;
Drug Therapy
- MeSH:
Adult;
Aged;
Antibodies, Antinuclear/blood;
Female;
Follow-Up Studies;
Humans;
Idiopathic Interstitial Pneumonias/drug therapy/pathology;
Lung Diseases, Interstitial/*drug therapy/mortality/pathology;
Male;
Middle Aged;
Prognosis;
Recurrence;
Retrospective Studies;
Steroids/*therapeutic use
- From:Journal of Korean Medical Science
2012;27(6):661-667
- CountryRepublic of Korea
- Language:English
-
Abstract:
The purpose of this study was to investigate the long-term clinical course of non-specific interstitial pneumonia (NSIP) and to determine which factors are associated with a response to steroid therapy and relapse. Thirty-five patients with pathologically proven NSIP were included. Clinical, radiological, and laboratory data were reviewed retrospectively. The male-to-female ratio was 7:28 (median age, 52 yr). Thirty (86%) patients responded to steroid therapy, and the median follow-up was 55.2 months (range, 15.9-102.0 months). Five patients (14%) showed sustained disease progression and three died despite treatment. In the five with sustained disease progression, NSIP was associated with various systemic conditions, and the seropositivity of fluorescent antinuclear antibody was significantly associated with a poor response to steroids (P = 0.028). The rate of relapse was 25%, but all relapsed patients improved after re-treatment. The initial dose of steroids was significantly low in the relapse group (P = 0.020). In conclusion, progression is associated with various systemic conditions in patients who show progression. A low dose of initial steroids is significantly associated with relapse.
